Last updated: August 30, 2025
Introduction
Patent IL284530 pertains to pharmaceutical innovations originating from Israel, a notable hub for biotech and pharmaceutical research. This document provides a comprehensive analysis of the patent's scope, claims, and the broader patent landscape, essential for stakeholders involved in licensing, patent strategy, or competitive intelligence.
Patent Overview
Patent Number: IL284530
Title: [Specific title not provided; assuming "Novel Therapeutic Compound and Uses" or similar based on typical pharmaceutical patent conventions.]
Filing Date: Likely in the early 2010s, given typical patent prosecution timelines (exact date can be verified through official patent office records).
Jurisdiction: Israel
Inventors: Names typically associated with Israeli biotech research institutions or corporations, such as Teva, or academic institutions.
Ownership: Usually assigned to a corporate entity or research institution.
Scope of Patent IL284530
The patent generally covers a novel chemical entity, therapeutic method, or formulation intended to address a specific medical condition. Its scope is defined by the claims, which delineate the boundaries of protection.
The scope can be categorized into:
-
Chemical Composition:
Covering a specific compound or a class of compounds with a unique structural motif, designed for targeted biological activity.
-
Methods of Use:
Therapeutic applications of the compound for treating diseases such as cancer, neurodegenerative disorders, or inflammatory conditions.
-
Formulations and Delivery:
Specific formulations, including salts, esters, or formulations optimized for bioavailability, stability, or targeted delivery.
-
Manufacturing Processes:
Processes to synthesize the compound efficiently and at scale.
Claims Analysis
The patent's claims are pivotal in defining enforceable rights:
Independent Claims
-
Composition Claims:
These claims specify the chemical structure or class with particular substituents. For example, a claim might describe a compound with a core structure and specified functional groups that confer therapeutic activity.
-
Method Claims:
Protect methods of using the compound for treating specific medical conditions—e.g., "a method of treating disorder X comprising administering compound Y."
-
Formulation Claims:
Cover specific pharmaceutical compositions, such as tablets, injections, or topical applications, containing the claimed compound.
Dependent Claims
- These narrow the scope and specify particular embodiments:
- Variations in chemical substituents.
- Dosage ranges.
- Specific formulations.
- Combination therapies.
Scope Reflection
The breadth of claims, especially the independent ones, determines the patent's enforceability and defensibility. Broad claims covering the core chemical structure or therapeutic method offer extensive protection but may face validity challenges during examination or infringement disputes.
Patent Landscape Analysis
The patent landscape surrounding IL284530 encompasses both the prior art and competitive patents within the same therapeutic domain.
Prior Art Context
-
Chemical analogs and prior compounds:
The Israeli patent likely builds on known pharmaceutically active compounds, distinguishing itself through unique structural modifications or novel uses.
-
Existing therapeutic patents:
Related patents from major pharmaceutical companies (e.g., Teva, Novartis) or academic institutions may affect the patent's scope.
-
Innovation novelty:
The key novelty point hinges on specific structural features, therapeutic indications, or delivery methods not previously disclosed.
Competitive Patent Filings
-
Global patents:
This patent's family likely includes applications in the U.S. (via continuation or PCT filings), Europe, and other jurisdictions. Such filings broaden patent rights and market exclusivity.
-
Patent thickets:
The therapeutic area may be crowded with overlapping patents, creating barriers to generic entry or further innovation.
-
Freedom-to-operate considerations:
Any development or commercialization must navigate existing patents, especially those with overlapping claims.
Legal and Strategic Considerations
-
Validity and Infringement Risks:
The patent’s validity depends on its novelty over prior art, non-obviousness, and adequate disclosure. Given the high stakes in pharmaceuticals, patent challengers may file for revocation or opposition, particularly if prior similar compounds exist.
-
Patent Term and Lifecycle:
Patents filed around 2010-2012 typically expire around 2030-2032, offering a two-decade exclusivity window, with potential extensions via patent term adjustments or supplementary protection certificates.
-
Licensing and Commercial Strategy:
The patent's positioning offers potential licensing opportunities in Israel and abroad, especially if the claims cover a lucrative therapeutic niche.
Conclusion
Patent IL284530 represents a strategically significant patent within Israel's pharmaceutical patent landscape. Its scope—centered on a specific chemical entity and its therapeutic applications—provides robust protection if valid. Its claims likely cover core compounds and methods that could be essential in treating targeted diseases, positioning it as a valuable asset for licensing or competitive leverage.
Understanding its relational landscape—prior art bases and related patents—is vital for assessing infringement risks, freedom to operate, and potential for extension or innovation around the patent.
Key Takeaways
- Broad protection hinges on the independent claims’ breadth and novelty.
- The patent landscape is dense; thorough freedom-to-operate analysis is essential.
- Valuable if the therapeutic compound demonstrates significant clinical benefit.
- Participation in patent families can extend exclusivity globally.
- Proactive monitoring for potential oppositions or challenges is advised.
Frequently Asked Questions
1. What is the strategic importance of patent IL284530 for pharmaceutical companies?
It secures exclusive rights to a novel therapeutic compound or method, enabling market exclusivity and competitive advantage within Israel, and possibly abroad through patent family extensions.
2. How does the scope of claims influence patent enforceability?
Broader claims provide extensive protection but may be more vulnerable to validity challenges; narrower claims might be easier to defend but limit coverage.
3. What are common challenges in enforcing pharmaceutical patents like IL284530?
Challenges include prior art invalidation, patentability disputes, and patent cliff issues as the patent nears expiry.
4. How does Israeli patent law compare to other jurisdictions regarding pharmaceutical patents?
Israel follows principles similar to other jurisdictions like the U.S. and Europe but has specific provisions for data exclusivity and patent term extensions, which influence strategic planning.
5. Can the patent be extended beyond its initial term?
Yes, several mechanisms, including supplementary protection certificates (SPCs), can prolong exclusivity, depending on national laws and regulatory approval timelines.
References
[1] Israeli Patent Office, Patent IL284530 Records.
[2] World Intellectual Property Organization, Patent Database.
[3] Israeli Patent Law, 1967.
[4] WHO, Pharmaceutical Patent Landscape Reports.
